Home Forums Other Specialities Oncology Immune check point inhibitors and CVS events

This topic contains 1 voice and has 0 replies.
1 voice
0 replies
  • Author
  • #3276

    Published in Oncology and
    Journal Scan / Research · July 21, 2022

    Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
    Journal of Clinical Oncology

    This retrospective, single-center, matched cohort study evaluated the incidence of and risk factors for cardiovascular events in 672 patients with a malignancy treated with immune checkpoint inhibitors and compared these patients with two separate controls (those who did not receive immune checkpoint inhibitors and those without a history of cancer).

    The incidence rate of major adverse cardiac events (MACE; acute coronary syndrome, heart failure, stroke, and transient ischemic attack) was 10.3%, and a history of heart failure or valvular disease was associated with an increased risk of MACE in the multivariate analysis.

    The cumulative incidence rate of MACE was significantly greater in the test group than in the two control groups.
    This large retrospective study demonstrates that MACE is potentially more common with immune checkpoint inhibitor use than previous studies have indicated.

    G Mohan.

You must be logged in to reply to this topic.